📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Alivus Life Sciences to Resume API Production at Fire-Affected Dahej Block by March 1, 2026
Alivus Life Sciences has provided a recovery update following a fire incident on February 14, 2026, at its Dahej manufacturing facility. The incident was confined to only one of the seven production blocks, primarily affecting intermediate manufacturing while API facilities remained intact. The company expects to resume API production in the affected block by March 1, 2026, and intermediate production by mid-March 2026. While some shipments will be delayed, the remaining six blocks continue to operate at full capacity, limiting the overall financial impact.
Key Highlights
Fire incident on Feb 14 was restricted to 1 out of 7 production blocks at the Dahej facility
API manufacturing facilities within the affected block were not damaged and remain unaffected
API production in the affected block is scheduled to resume on March 1, 2026
Intermediate manufacturing is expected to restart by mid-March 2026
Six other production blocks at the site remain fully operational with only minor shipment delays expected
💼 Action for Investors
Investors should view this as a minor operational disruption with a clear recovery timeline. Monitor the upcoming quarterly results for any one-time costs or insurance claims related to this incident.
Alivus Life Sciences Reports Fire at Dahej API Plant; 3 Injured, Production Suspended
Alivus Life Sciences reported a fire incident at its Dahej API manufacturing facility on February 14, 2026. The fire resulted in three injuries and led to the temporary suspension of production operations at the site. While the fire was controlled within an hour, the company is currently assessing the extent of the damage and investigating the root cause. The company has confirmed that it has adequate insurance coverage to mitigate financial losses.
Key Highlights
Fire broke out at the Dahej API plant on February 14, 2026, around 23:00 Hrs
Three injuries were reported among the staff during the incident
Production operations at the facility are temporarily suspended pending damage assessment
The fire was brought under control within one hour by the factory team
The company maintains adequate insurance coverage for the potential losses
💼 Action for Investors
Investors should monitor the duration of the production suspension and the subsequent assessment of financial damage. While insurance provides a safety net, any prolonged shutdown could impact short-term revenue from the API segment.
Alivus Life Sciences Q3 FY26: Record Revenue of ₹673 Cr and Highest Ever EBITDA Margin of 36.4%
Alivus Life Sciences reported its highest-ever quarterly revenue of ₹673 crores, driven by a strong recovery in the CDMO business which grew 85.3% YoY. The company achieved record EBITDA margins of 36.4%, leading to a revised upward margin guidance of 30-32% for the future. Despite a slight delay in the Solapur expansion project, the company remains net debt-free with a strong cash position of ₹733 crores. The non-GPL segment continues to be a primary growth driver, expanding 16.1% in the first nine months of FY26.
Key Highlights
Reported highest-ever quarterly revenue of ₹673 crores, up 14.4% QoQ and 4.8% YoY
EBITDA margins reached a record 36.4%, up 510 bps YoY, driven by favorable product mix and efficiency
CDMO segment showed exceptional recovery with 100% QoQ and 85.3% YoY revenue growth
Management raised long-term EBITDA margin guidance to 30%-32% from the previous 28%-30%
FY26 CAPEX guidance revised to ₹450 crores from ₹600 crores, with ₹150 crores deferred to FY27
💼 Action for Investors
Investors should take note of the significant margin expansion and CDMO recovery as signs of structural business improvement. The company's debt-free status and high-potent API pipeline provide a strong long-term growth outlook.
Alivus Life Sciences Q3 FY26: EBITDA Margins Surge to 36.4% Amid Strong CDMO Recovery
Alivus Life Sciences reported a robust Q3 FY26 with revenue growing 14.4% QoQ to ₹6,729 million, primarily driven by a 100% QoQ turnaround in the CDMO segment. EBITDA margins expanded significantly to 36.4%, up 510 bps YoY, due to a better product mix and operational efficiencies. The company generated ₹2,207 million in free cash flow during 9MFY26, maintaining a strong cash position of ₹7,330 million. Management is executing an aggressive expansion strategy, aiming to nearly double reactor capacity to 2,690 KL by FY28.
Key Highlights
Q3 FY26 revenue stood at ₹6,729 million, up 14.4% QoQ and 4.8% YoY.
CDMO business revenue grew 100% QoQ and 85.3% YoY, driven by new project contributions.
EBITDA margins reached 36.4%, a substantial improvement of 510 bps over the previous year.
Non-GPL business grew 16.1% YoY in 9MFY26, now contributing 70% of total revenue.
Planned capacity expansion to 2,690 KL by FY28 from current 1,424 KL to support future growth.
💼 Action for Investors
The sharp recovery in CDMO and significant margin expansion are highly positive signals for profitability. Investors should monitor the execution of the Solapur greenfield project and the continued growth of the non-GPL business as key long-term value drivers.
Alivus Life Sciences Reports Record Q3 Revenue of Rs 6,729 Mn and 36.4% EBITDA Margin
Alivus Life Sciences achieved its highest-ever quarterly revenue of Rs 6,729 million in Q3FY26, representing a 14.4% sequential growth. The company reported record EBITDA margins of 36.4%, driven by a recovery in the CDMO segment and a favorable product mix. Profit After Tax (PAT) grew by 15.5% QoQ to Rs 1,503 million, while the company remains net debt-free with cash reserves of Rs 7,330 million. Management expects to sustain this growth momentum through new product launches and expansion into complex chemistry.
Key Highlights
Record quarterly revenue of Rs 6,729 Mn, up 14.4% QoQ and 4.8% YoY.
Highest ever EBITDA margin of 36.4%, expanding by 510 bps YoY and 340 bps QoQ.
9MFY26 PAT increased by 16.9% YoY to Rs 4,019 Mn with a healthy 21.6% margin.
Strong liquidity position with Rs 7,330 Mn in cash and free cash flow generation of Rs 2,207 Mn.
Expansion updates include 465 KL capacity addition at Solapur and a new R&D center land acquisition in Taloja.
💼 Action for Investors
Investors should view the record margins and CDMO recovery as strong bullish signals for the company's operational efficiency. The debt-free balance sheet and ongoing capacity expansion provide a solid foundation for long-term growth in the high-value API space.
Alivus Life Sciences Q3 Net Profit Rises 9.7% YoY to ₹150.26 Cr; Revenue up 4.8%
Alivus Life Sciences reported a steady performance for Q3 FY26, with revenue from operations growing 4.8% YoY to ₹672.89 crore. Net profit increased by 9.7% YoY to ₹150.26 crore, despite a one-time exceptional charge of ₹25.66 crore due to the implementation of new statutory labour codes. On a sequential basis, the company showed strong recovery with revenue and PAT growing by 14.4% and 15.5% respectively compared to Q2 FY26. The core API business remains the sole driver of growth, maintaining healthy margins.
Key Highlights
Revenue from operations grew 14.4% QoQ to ₹6,728.89 million.
Net profit stood at ₹1,502.61 million, up from ₹1,369.60 million in the same quarter last year.
Reported an exceptional item of ₹256.57 million for statutory impacts of new labour codes (gratuity and absences).
Basic EPS improved to ₹12.25 from ₹11.18 YoY.
Total income for the nine-month period reached ₹19,003.48 million compared to ₹17,618.21 million last year.
💼 Action for Investors
The company shows resilient growth and strong sequential recovery in its core API business. Investors should maintain a positive outlook as the operational performance remains robust despite the one-time regulatory-driven cost adjustment.